



PRESS RELEASE

Rheon Medical announces CE mark approval for eyeWatch system

Lausanne, Switzerland, 17 December 2019. Rheon Medical SA today announced that it has received the CE mark for its first-in-class eyeWatch system, which is used for the surgical treatment of glaucoma. This marks the start of commercialization of the eyeWatch system in Europe.

The eyeWatch system will be sold directly by Rheon Medical in Switzerland and other key countries, while distribution agreements will be established for the rest of the territory.

“The CE approval is an important milestone in the development of the company and we are excited to start serving the community of glaucoma patients so much in need for safer and better performing surgical solutions”, said Nikos Stergiopoulos CEO of Rheon Medical. “We have completed a thorough clinical program in Switzerland, Greece and the UK. More than 140 patients have been treated with the eyeWatch system producing outstanding results. We are now confident that we can offer to our glaucoma patients the best possible care.”

Thomas Zehnder, Chairman of Rheon Medical and General Partner of Blue Ocean Ventures SA added “As an early investor in Rheon Medical, we are extremely pleased about the CE mark approval. This achievement will allow the company to rapidly expand their key opinion leader network across Europe and other regions, where the CE mark is relevant.”

About the eyeWatch system

Glaucoma is a leading cause of blindness affecting more than 70 million people worldwide. Glaucoma is most often due to an increase of intraocular pressure (IOP), which may result in damage of the optic nerve and, if untreated, in vision loss. Aqueous shunts (glaucoma drainage devices) have been increasingly used to lower IOP and they are now considered by many to be the first-line surgical intervention. Presently marketed shunts exhibit post-surgical complications at a fairly high rate (>30%) and often lead to surgical failures, a significant part of which can be attributed to the lack of intraocular pressure control. The eyeWatch™ system is a unique ocular implant, which together with its external control device allows tight control over intraocular pressure. Pressure control leads to better and safer therapy. For details on the technology and the clinical benefits please see www.rheonmedical.com.

About Rheon Medical SA

Rheon Medical is a privately held Swiss medical device company, a spin-off from the Swiss Federal Institute of Technology Lausanne (EPFL). Rheon Medical specializes in the field of glaucoma surgery and, in specific, in glaucoma drainage devices (GDD). Its mission is to provide optimal solutions to the surgical therapy of glaucoma. Rheon Medical is ISO 13485 certified.